Toronto - Free Realtime Quote CAD

Fennec Pharmaceuticals Inc. (FRX.TO)

Compare
7.02
0.00
(0.00%)
As of April 8 at 3:48:24 PM EDT. Market Open.
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
47,538
47,538
21,252
1,535
--
Cost of Revenue
3,184
3,184
1,259
86
--
Gross Profit
44,354
44,354
19,993
1,449
--
Operating Expense
41,786
41,786
32,764
24,038
17,223
Operating Income
2,568
2,568
-12,771
-22,589
-17,223
Net Non Operating Interest Income Expense
-2,476
-2,476
-3,240
-932
-88
Other Income Expense
-163
-163
-34
-193
-35
Pretax Income
-71
-71
-16,045
-23,714
-17,346
Tax Provision
365
365
--
--
--
Net Income Common Stockholders
-436
-436
-16,045
-23,714
-17,346
Diluted NI Available to Com Stockholders
-436
-436
-16,045
-23,714
-17,346
Basic EPS
-0.02
--
-0.60
-0.90
-0.67
Diluted EPS
-0.02
--
-0.60
-0.90
-0.67
Basic Average Shares
27,294
--
26,574
26,275
26,006
Diluted Average Shares
27,294
--
26,574
26,275
26,006
Total Operating Income as Reported
2,568
2,568
-12,771
-22,589
-17,223
Total Expenses
44,970
44,970
34,023
24,124
17,223
Net Income from Continuing & Discontinued Operation
-436
-436
-16,045
-23,714
-17,346
Normalized Income
-307.23
-307.23
-16,011
-23,521
-17,311
Interest Income
1,682
1,682
441
195
54
Interest Expense
4,069
4,069
3,394
978
126
Net Interest Income
-2,476
-2,476
-3,240
-932
-88
EBIT
3,998
3,998
-12,651
-22,736
-17,220
EBITDA
4,798
4,798
-12,651
-22,736
-17,220
Reconciled Cost of Revenue
3,184
3,184
1,259
86
--
Reconciled Depreciation
800
800
--
149
16
Net Income from Continuing Operation Net Minority Interest
-436
-436
-16,045
-23,714
-17,346
Total Unusual Items Excluding Goodwill
-163
-163
-34
-193
-35
Total Unusual Items
-163
-163
-34
-193
-35
Normalized EBITDA
4,961
4,961
-12,617
-22,543
-17,185
Tax Rate for Calcs
0
0
--
--
--
Tax Effect of Unusual Items
-34.23
-34.23
--
--
--
12/31/2021 - 6/12/2001

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

MBX.TO Microbix Biosystems Inc.
0.3650
-1.35%
 
MDNA.TO Medicenna Therapeutics Corp.
0.8800
+3.53%
 
COV.V Covalon Technologies Ltd.
2.3300
+3.10%
 
APS.TO Aptose Biosciences Inc.
3.0000
-11.76%
 
ONC.TO Oncolytics Biotech Inc.
0.6900
-1.43%
 
EWTX Edgewise Therapeutics, Inc.
10.96
-4.61%
 
AVXL Anavex Life Sciences Corp.
7.69
+1.18%
 
NVAX Novavax, Inc.
6.21
-1.58%
 
MRNA Moderna, Inc.
24.06
-2.37%